BLFS

Over the past six months, BioLife Solutions' stock has been impacted by several events. On July 21, 2026, Repligen Corporation announced an agreement to acquire BioLife Solutions for approximately $1.5 billion to $1.6 billion, with BioLife stockholders expected to receive $11.25 per share in cash and 0.1442 shares of Repligen common stock, totaling about $31.00 per share; this transaction is currently under legal scrutiny by shareholder law firms. The company reported Q2 2026 earnings on August 6, 2026, with an EPS of $0.92 (up from a $0.33 loss in Q2 2025) and revenue of $28.5 million (up 12% from Q2 2025), both exceeding analyst expectations. Q1 2026 earnings, reported on May 7, 2026, showed an EPS of $0.02. In July 2026, several analysts, including Zacks Research and TD Cowen, downgraded BioLife Solutions to a 'Hold' rating, establishing a current consensus 'Hold' rating. As of mid-September 2026, the stock demonstrated a strong 90-day share price return of 34.41% and a year-to-date return of 48.30%, with its 52-week range between $17.86 and $38.10.